Shopping Cart
Remove All
Your shopping cart is currently empty
Elipovimab
Catalog No. T77177 Copy Product Info
🥰Excellent
Elipovimab (GS-9722) is a humanized broadly neutralizing antibody (bNAb) targeting the V3 glycan supersite of the HIV-1 envelope glycoprotein gp120. As an Fc-optimized version of PGT121, it neutralizes viral particles and eliminates infected cells via antibody-dependent cellular cytotoxicity (ADCC). The antibody exhibits enhanced effector cell-mediated killing activity in the presence of TLR agonists.
Elipovimab
Copy Product Info🥰Excellent
Catalog No. T77177
Elipovimab (GS-9722) is a humanized broadly neutralizing antibody (bNAb) targeting the V3 glycan supersite of the HIV-1 envelope glycoprotein gp120. As an Fc-optimized version of PGT121, it neutralizes viral particles and eliminates infected cells via antibody-dependent cellular cytotoxicity (ADCC). The antibody exhibits enhanced effector cell-mediated killing activity in the presence of TLR agonists.
Elipovimab
Cas No. 2101210-43-7
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $622 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $996 | 2-4 weeks | 2-4 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Elipovimab (GS-9722) is a humanized broadly neutralizing antibody (bNAb) targeting the V3 glycan supersite of the HIV-1 envelope glycoprotein gp120. As an Fc-optimized version of PGT121, it neutralizes viral particles and eliminates infected cells via antibody-dependent cellular cytotoxicity (ADCC). The antibody exhibits enhanced effector cell-mediated killing activity in the presence of TLR agonists. |
| In vitro | In ex vivo assays using PBMCs from HIV-infected individuals, Elipovimab (GS-9722) demonstrates potent ADCC activity against cells expressing viral envelopes. Pre-treatment of NK cells with TLR7 or TLR9 agonists significantly increases Elipovimab-mediated killing of autologous HIV-infected CD4+ T cells and promotes more efficient target cell clearance [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | HIV-1 |
| Cas No. | 2101210-43-7 |
| Isotype | IgG1-ADLEEMLS |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Elipovimab | purchase Elipovimab | Elipovimab cost | order Elipovimab | Elipovimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.